AMNEAL PHARMACEUTICALS, INC. AMRX

19.77 (0.04) (0.20%) as of 25 Sep
Market cap
$6.3B
P/E
39.5×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
3,018.76 2,793.96 2,393.61 2,212.30 2,093.67 1,992.52 1,626.37 1,662.99 1,033.65 1,018.23
Revenue Growth
8.05% 16.73% 8.20% 5.67% 5.08% 22.51% (2.20%) 60.88% 1.52% 18.33%
Cost of Revenue
1,905.45 1,773.52 1,573.04 1,427.60 1,324.70 1,364.13 1,273.38 946.59 507.48 420.77
Gross Profit
1,113.31 1,020.44 820.56 784.71 768.97 628.39 353.00 716.40 526.18 597.46
R&D Expenses
186.18 190.71 163.95 195.69 201.85 179.93 188.05 194.19 171.42 179.02
SG&A Expenses
526.83 476.44 429.68 399.70 365.50 326.73 289.60 227.85 109.05 118.76
Operating Income
394.10 249.33 204.37 (94.93) 152.72 91.15 (248.68) (19.67) 245.10 284.88
Non-operating Income/Expense
(254.89) (304.34) (244.64) (153.20) (121.35) (126.93) 28.44 (183.05) (73.78) (70.06)
Non-operating Interest Expenses
241.09 258.60 210.63 158.38 136.33 146.00 168.21 143.57 71.06 55.28
EBT
139.21 (55.01) (40.27) (248.13) 31.37 (35.78) (220.24) (202.72) 171.32 214.82
Income Tax Provision
11.28 18.86 8.45 6.66 11.20 (104.36) 383.33 (1.42) 2.00 5.40
Income after Tax
127.93 (73.88) (48.72) (254.79) 20.17 68.58 (603.57) (201.30) 169.33 209.43
Dividends (Preferred)
— — — 0.00 0.00 0.00 — (148.81) 167.65 207.38
Non-Controlling Interest
55.88 43.01 35.27 (124.80) 9.55 (22.48) (241.66) (31.58) 1.68 2.05
Net Income Common
72.06 (116.89) (83.99) (129.99) 10.62 91.06 (361.92) (20.92) — 0.00
EPS (Basic)
0.23 (0.38) (0.48) (0.86) 0.07 0.62 (2.74) (1.58) (6.53) (6.63)
EPS (Diluted)
0.22 (0.38) (0.48) (0.86) 0.07 0.61 (2.74) (1.58) (6.53) (6.63)
Shares (Basic, Weighted)
313.37 308.98 176.14 150.94 148.92 147.44 132.11 127.25 74.00 71.00
Shares (Diluted, Weighted)
324.81 308.98 176.14 150.94 151.82 148.91 132.11 127.25 74.00 71.00
Gross Margin
36.88% 36.52% 34.28% 35.47% 36.73% 31.54% 21.70% 43.08% 50.90% 58.68%
EBIT Margin
13.05% 8.92% 8.54% (4.29%) 7.29% 4.57% (15.29%) (1.18%) 23.71% 27.98%
EBT margin
4.61% (1.97%) (1.68%) (11.22%) 1.50% (1.80%) (13.54%) (12.19%) 16.57% 21.10%
Net Profit Margin
2.39% (4.18%) (3.51%) (5.88%) 0.51% 4.57% (22.25%) (1.26%) 0.00% 0.00%
Free Cash Flow Margin
7.54% 7.88% 11.55% (1.15%) 9.27% 15.70% (5.89%) 10.73% 11.60% (0.94%)
EBITDA
640.10 514.61 445.32 153.84 395.32 335.22 1.42 134.01 295.62 320.95
EBIT
394.10 249.33 204.37 (94.93) 152.72 91.15 (248.68) (19.67) 245.10 284.88
Income from Continuous Operations
127.93 (73.88) (48.72) (254.79) 20.17 68.58 (603.57) (201.30) 169.33 209.43
Consolidated Net Income/Loss
127.93 (73.88) (48.72) (254.79) 20.17 68.58 (603.57) (201.30) 169.33 209.43
EPS (Basic, from Continuous Ops)
0.41 (0.24) (0.28) (1.69) 0.14 0.47 (4.57) (1.58) — —
EPS (Basic, Consolidated)
0.41 (0.24) (0.28) (1.69) 0.14 0.47 (4.57) (1.58) — —
EPS (Diluted, from Cont. Ops)
0.39 (0.24) (0.28) (1.69) 0.13 0.46 (4.57) (1.58) — —
Shares (Diluted, Average)
324.81 308.98 176.14 150.94 151.82 148.91 132.11 127.25 71.86 71.15
EPS (Diluted, Consolidated)
0.39 (0.24) (0.28) (1.69) 0.13 0.46 (4.57) (1.58) — —
EBITDA Margin
21.20% 18.42% 18.60% 6.95% 18.88% 16.82% 0.09% 8.06% 28.60% 31.52%
Operating Cash Flow Margin
11.26% 10.56% 14.44% 2.94% 11.55% 19.02% 0.10% 15.05% 22.66% 11.30%

Fold the line items

In millions of $ except per-share values · columns are period end dates